In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.
01 Nov 2017
AIM – A Decade of Achievement
Sinclair Pharma (SPH:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Scancell Holdings Plc (SCLP:LON), 9.6 | Allergy Therapeutics plc (AGY:LON), 2.8 | City of London Investment Group PLC (CLIG:LON), 319 | Tissue Regenix Group plc (TRX:LON), 61.5 | Avacta Group PLC (AVCT:LON), 47.0 | Alliance Pharma plc (APH:LON), 37.0 | Chamberlin plc (CMH:LON), 1.2 | Murgitroyd Group (MUR:LON), 0 | ValiRx PLC (VAL:LON), 3.4
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
AIM – A Decade of Achievement
Sinclair Pharma (SPH:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Scancell Holdings Plc (SCLP:LON), 9.6 | Allergy Therapeutics plc (AGY:LON), 2.8 | City of London Investment Group PLC (CLIG:LON), 319 | Tissue Regenix Group plc (TRX:LON), 61.5 | Avacta Group PLC (AVCT:LON), 47.0 | Alliance Pharma plc (APH:LON), 37.0 | Chamberlin plc (CMH:LON), 1.2 | Murgitroyd Group (MUR:LON), 0 | ValiRx PLC (VAL:LON), 3.4
- Published:
01 Nov 2017 -
Author:
Nigel Hawkins -
Pages:
42
In the November edition of the Hardman Monthly Newsletter, Nigel Hawkins assesses the achievements of AIM – and how it has thrived, despite a challenging financial environment, in recent years.